Actively Recruiting
A French Observational Study of Adult Male Patients Using Olaparib for Metastatic Castration-resistant Prostate Cancer in Real-life Settings
Led by AstraZeneca · Updated on 2026-06-02
300
Participants Needed
65
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a French non-interventional longitudinal multicenter cohort study to evaluate the added value of olaparib for treating patients with metastatic castration-resistant prostate cancer mCRPC in real-world settings. The study aims to assess treatment sequencing, effectiveness, safety, and BRCA testing patterns, helping to inform future clinical practice. This observational study is sponsored by AstraZeneca. The study observes adult male patients who have started olaparib treatment within at least the last two months or who participated in a funded early access program. There are no assigned treatment groups or interventions beyond olaparib use as decided by their physician. Data collection continues up to 32 months to capture treatment patterns and patient characteristics. Participants data on treatment duration, disease progression, therapy sequences, symptomatic skeletal events, and BRCA testing timing will be collected and analyzed up to 24 months from olaparib initiation. Socio-demographic and clinical characteristics of patients and physicians will be gathered at the end of enrollment. The study monitors reasons for dose changes, interruptions, and treatment cessation, ensuring comprehensive real-world evidence about olaparib in mCRPC patients.
CONDITIONS
Brief Title
PRostate Olaparib Real World Evidence Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult male patients aged 18 years or older
- Diagnosed with metastatic castration-resistant prostate cancer
- Have started olaparib treatment within at least the last two months of study entry or enrolled in a funded early access program
- Have been informed about the study and do not oppose data collection
- For patients in early access: still alive and informed about the study or deceased without objection to data use during lifetime
You will not qualify if you...
- Patients opposed to the collection of their data
- Patients participating in a clinical trial with an investigational prostate cancer targeted drug within 30 days prior to olaparib initiation
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here